A new book shows how Johnson & Johnson has pushed misleading narratives and suppressed inconvenient findings to sell its ...

An investigative history of the scandal-plagued company shines a light on a health care industry riddled with corruption and criminality.

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Johnson & Johnson has reported data from a Phase I trial of pasritamig for metastatic castration-resistant prostate cancer ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

Commissioner Makary touts dubious evidence on talcum powder at a rushed hearing.

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

Johnson & Johnson recently garnered attention when the FDA's Oncologic Drugs Advisory Committee voted favorably on the use of DARZALEX FASPRO® for high-risk smoldering multiple myeloma.

The Hatch-Waxman Act of 1984—which lowered barriers for smaller drug companies to introduce nonbrand versions of drugs whose patents had expired—was negotiated just as bigs like Johnson ...

Bryan Johnson, a tech entrepreneur, claims to have reversed aspects of his biological age to that of a pre-teen through ...